期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
Improving Cost Savings and Patient Outcomes with Hepatitis C Triple Therapy Treatment in the Medicaid Population
1
作者 Yongjie Chen Christine Carter +5 位作者 Meredith Fish DanieUe Mayer Richard Algoo Sheena Cherian James Cavage Jamila Jorden 《Journal of Pharmacy and Pharmacology》 2014年第8期470-481,共12页
One of the major infections that plague our world today, hepatitis C, has been causing liver disease in humans since early history. Over time, human ingenuity has allowed us to develop more effective treatments, but a... One of the major infections that plague our world today, hepatitis C, has been causing liver disease in humans since early history. Over time, human ingenuity has allowed us to develop more effective treatments, but at traditionally massive monetary costs. In order to combat such costs, PerformRx came up with three ways to drive costs downward but also increase different outcomes for the Pennsylvania Medicaid population it serves. By restricting access to drugs via prior authorizations, tracking members within a DTM (drug therapy management) program, and giving members touchscreen tablet devices, there was an observed cost savings and a better ability to service members. Even though there was little impact on overall member outcomes, these initial interventions were the right steps to be innovative and create a beneficial scenario for both members and clients. 展开更多
关键词 Hepatitis C TABLET prior authorization triple therapy targeted medication review PerformRx.
暂未订购
上一页 1 下一页 到第
使用帮助 返回顶部